348:. Unlike lipid nanoparticles which can only take on a spherical shape, polymersomes can be formed into various shapes such as discs, ellipsoids, and tubes. Methods such as thin film rehydration and direct injection result in polymersomes of variable sizes. Others such as polymerization induced self-assembly and flash nanoprecipitation are more consistent manufacturing methods with regards to size. These particles are more stable than phospholipid vesicles, featuring higher levels of strain before breakdown. This is particularly useful as it allows for adhesion at sites of inflammation where there are considerable shear forces. The thicker membranes and arrangement of hydrophobic chains of polymersomes greater stability and drug retention within the body. The surface of polymersomes is compatible with both covalent and non-covalent conjugation chemistry which can be used to target specific tissues and cellular surfaces. An early study from 2003 developed a method for producing "PLGA microspheres" that can be loaded with anti-inflammatory drugs, adhere to sites of inflammation, and release the loaded drug via selectin and ligand chemistry. These in concept are early versions of polymersomes. Polymersomes can mimic antigen presenting cells when loaded with tumor antigens to elicit a stronger immunogenic response, effectively acting as nanovaccines. Leukopolymersomes have the potential to be used as treatment for inflammation and cancer.
378:, and then sonicating the empty cell membranes to create nanoghosts between 100 and 200 nm in diameter. Membranes used to make nanoghosts harvested form red blood cells have been shown to circulate for about 120 days and avoid phagocytotic cells. Neutrophil based nanoghosts retain the chemotaxis capacity of neutrophils to sites of inflammation, which encourages tumor targeting. NK based nanoghosts exhibit metastatic cancer targeting behavior. Monocyte based nanoghosts are effective at infiltrating the tumor microenvironment.
252:
functions, including activation of other cells such as B-cells, helper T-cells and CD4+ cells, as well as elimination of virally infected cells and cancer cells. NK cells are involved in the innate immune system, and they kill pathogens via release of perforin and granzyme to directly destroy cell membranes, release of cytokines such as TNF-α to boost activity of other WBCs, as well as secretion of signals that trigger apoptosis. NK cells also can act to destroy pathogens without prior stimulation, unlike T-Cells.
309:
153:. There exists leukocytes that do not circulate but instead remain in a particular tissue. These include histiocytes and dendritic cells. They typically range in size from 8 to 18 μm in diameter depending on cell type and stage in development. Leukocytes make up roughly 1% of the total blood cells in the average human body. Leukocytes maintain the expression of CD47 and CD45 biomarkers which indicate to other cells what they are and that they should not be destroyed. Cells like
366:
114:
287:
to preferentially target inflamed endothelial tissue both in vitro and in vivo. They are typically manufactured by harvesting immune cells from an organism, most often mice, and disposing of all native components except the plasma membrane. Once the plasma membrane is isolated, it is enriched with proteins to give the particle a similar composition to the desired subject's leukocytes, and loaded with therapeutic membrane soluble compounds such as
400:
for standard clinical use. Some studies have also found that these particles may unintentionally target other tissues that are otherwise healthy. The delivery of the therapies faces some difficulties in that too rapid administration might cause systemic side effects, whereas a too slow release would be less effective. A major limitation to polymersomes is that a select number of polymers such as
261:
feature, and more to do with creating simple vesicle-like particles the size of actual immune cells that are capable of performing tasks and mimicking the physiological features of biological immune cells to an efficacious degree. The main mechanisms in particular that are commonly mimicked in artificial WBCs are the release of cytotoxic compounds and ability to perform phagocytosis.
25:
315:
314:
311:
310:
295:, the leukosomes were able to accumulate in sites of inflammation and reduce expression of pro-inflammatory markers. Other studies found that leukosomes decrease expression of pro-inflammatory genes while increasing expression of anti-inflammatory genes, exhibiting promise as a treatment method for inflammatory diseases. In one study, leukosomes loaded with
316:
313:
404:
and poly(lactic-co-glycolic acid) are approved by the FDA for clinical use. Nanoghosts, or more generally membrane-coated nanoparticles, experience limitations in that cells will have varying degrees of proteins present in their membranes, creating variability and lack of stability in those products.
373:
Nanoghosts are nanosized vesicles containing a chosen drug delivery payload manufactured from extracted leukocyte membranes with the cell cytoplasm content removed. The use of biological membranes serves to mask the particles from the immune system to reduce the likelihood of an immunogenic response,
399:
The major limitation in the development of artificial WBCs is the translation of the technologies into clinical approval and use. Other limitations include the availability of technology necessary to produce artificial WBCs, variability in yield, and difficulties in purifying the particles necessary
286:
with embedded proteins that are found in the membranes of naturally produced leukocytes. Leukosome particles exhibit similar mechanical and physiological qualities to leukocytes while also benefiting from the advantages of liposomal manufacturing and therapeutic administration. Leukosomes were shown
251:
to bind and tag unwanted antigens for destruction and digestion. Once activated, they immediately begin producing antibodies for urgent action, or they circulate around the body as memory B cells to serve as protection against a particular antigen for long periods of time. T-cells have several key
198:
Eosinophils are weaker than neutrophils at performing phagocytosis and effectively diminishing infectious pathogen populations. However, they excel at targeting and eliminating certain parasitic organisms through release of granules containing toxic proteins, including RNAases which are effective
356:
Leukolike vectors are a type of nanoparticles made of nanoporous silicon encapsulated by extracted native leukocyte membranes. These particles were among the first artificial white blood cells to be studied as a proof of concept of using cellular membranes to prolong circulation of nanoparticles
299:
injected into murine models inhibited breast and melanoma tumor growth more effectively than dissolved circulating doxorubicin. Another study examined the differences in therapeutic behavior between liposomes and leukosomes both loaded with doxorubicin and found that unlike liposomes the loaded
260:
Research into artificial WBCs began around the time as artificial red blood cells as an effort to address the lack of whole blood donations available for emergencies. The artificial WBCs developed since the 2000s have less to do with reproducing exact replicas of immune cells with their every
1016:
Parodi, Alessandro; Quattrocchi, Nicoletta; van de Ven, Anne L.; Chiappini, Ciro; Evangelopoulos, Michael; Martinez, Jonathan O.; Brown, Brandon S.; Khaled, Sm Z.; Yazdi, Iman K.; Enzo, Maria
Vittoria; Isenhart, Lucas; Ferrari, Mauro; Tasciotti, Ennio (December 16, 2012).
405:
There also is the risk that membrane proteins essential to the biomimetic function of the nanoghosts can become denatured in the manufacturing and storage process. Overall, more studies need to be done on these biomimetic solutions to verify efficacy and safety.
390:
Artificial
Antigen Presenting Cells (aAPCs) are polystyrene beads with stimulating receptor ligands. aAPCs loaded with cytokines have been found to stimulate T-cells to a higher degree than particles containing solely costimulatory ligands.
181:
to activate other types of leukocytes. The distinct chemotaxis behavior of neutrophils allows for localized targeting of cancer sites using manipulated neutrophils. Neutrophils are the first to fend off pathogens and achieve such through
722:
Molinaro, Roberto; Martinez, Jonathan O.; Zinger, Assaf; Vita, Alessandro De; Storci, Gianluca; Arrighetti, Noemi; Rosa, Enrica De; Hartman, Kelly A.; Basu, Nupur; Taghipour, Nima; Corbo, Claudia; Tasciotti, Ennio (2019-12-17).
656:
Molinaro, R.; Corbo, C.; Martinez, J. O.; Taraballi, F.; Evangelopoulos, M.; Minardi, S.; Yazdi, I. K.; Zhao, P.; De Rosa, E.; Sherman, M. B.; De Vita, A.; Toledano Furman, N. E.; Wang, X.; Parodi, A.; Tasciotti, E. (May 2016).
357:
throughout the blood. Studies have shown that leukolike vectors have a specific advantage in chemotherapy drug delivery to cancer. This is because leukolike vectors specifically have the potential to bind to tumor endothelium.
312:
177:, neutrophils are typically found migrating toward sites of inflammation that are secreting heightened concentrations of inflammatory chemical signals. Once they arrived at the site of inflammation, they release
100:
or deliver drugs in a more favorable fashion. While certain limitations have prevented leukocyte mimicking particles from becoming widely used and FDA approved, more research is being allocated to this area of
778:
Rampado, Riccardo; Biccari, Andrea; D'Angelo, Edoardo; Collino, Federica; Cricrì, Giulia; Caliceti, Paolo; Giordano, Federica; Taraballi, Francesca; Pucciarelli, Salvatore; Agostini, Marco (2022).
598:
Bagasariya, Deepkumar; Charankumar, Kondasingh; Shah, Saurabh; Famta, Paras; Khatri, Dharmendra Kumar; Singh
Raghuvanshi, Rajeev; Bala Singh, Shashi; Srivastava, Saurabh (2022-08-01).
133:, as well as cells turned cancerous. They mainly circulate throughout the vasculature including capillary beds, bone marrow, and lymph vessels. The five major types of WBCs are
948:
Hammer, Daniel A.; Robbins, Gregory P.; Haun, Jered B.; Lin, John J.; Qi, Wei; Smith, Lee A.; Ghoroghchian, P. Peter; Therien, Michael J.; Bates, Frank S. (2008-08-18).
96:
for use in emergency blood transfusions, research into artificial white blood cells has been focused on increasing the immunogenic response within a host to treat
780:"Optimization of Biomimetic, Leukocyte-Mimicking Nanovesicles for Drug Delivery Against Colorectal Cancer Using a Design of Experiment Approach"
275:
74:
488:
467:
Rahman, Khaliqur; Alam, Mohammad Feroz (2022-01-01), Denizli, Adil; Nguyen, Tuan Anh; Rajan, Mariappan; Alam, Mohammad Feroz (eds.),
300:
leukosomes better incorporated themselves into surrounding cells in vitro and served as an effective drug depot for the doxorubicin.
125:(WBCs), come in various types and generally circulate around the body to facilitate warding off pathogenic invaders such as
374:
as well as to extend circulation of the particles in the blood. They are produced by homogenizing the cells to remove the
369:
A theoretical image of an intact cellular membrane of a nanoghost nanoparticle, including the expressed surface proteins
207:
Primarily involved in allergic reactions, basophils release granules containing heparin, histamine, and proteolytic
1090:
1085:
211:. They possess similar anti-parasitic properties to eosinophils, as well as exhibit regulatory functions of
84:
are typically membrane bound vesicles designed to mimic the immunomodulatory behavior of naturally produced
162:
725:"Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma"
468:
1019:"Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions"
379:
852:
Scheerstra, J. F.; Wauters, A. C.; Tel, J.; Abdelmohsen, L. K. E. A.; van Hest, J. C. M. (2022-03-01).
902:
599:
525:
1080:
961:
670:
231:
to T-cells which produce immune system alerting signals upon coming into contact with said antigens.
158:
724:
401:
244:
54:
35:
883:
760:
635:
561:
494:
365:
113:
1056:
1038:
995:
977:
930:
922:
875:
819:
801:
752:
744:
704:
686:
627:
619:
553:
545:
484:
341:
336:
found in native leukocytes. Polymersomes are typically made of biodegradable polymers such as
105:
which has the potential for producing a new form of treatment for cancer and other diseases.
1046:
1030:
985:
969:
914:
865:
809:
791:
736:
694:
678:
611:
537:
476:
122:
102:
227:
that eliminate certain pathogens through phagocytosis. They serve a key role in presenting
337:
328:
that excel at mimicking the adhesive qualities of leukocytes, specifically the binding of
965:
674:
1051:
1018:
990:
949:
814:
779:
699:
658:
480:
288:
274:
154:
89:
918:
73:
1074:
887:
764:
639:
565:
498:
292:
187:
278:
A leukosome devoid of surface proteins and structures, otherwise known as a liposome
325:
183:
870:
853:
296:
615:
541:
796:
224:
223:
Once monocytes enter the region containing pathogens, they differentiate into
174:
150:
138:
134:
85:
1042:
981:
926:
879:
805:
748:
690:
623:
549:
526:"Biomimetic nano drug delivery carriers for treating cardiovascular diseases"
909:. Proceeding of the Seventh European Symposium on Controlled Drug Delivery.
44:
1060:
1034:
999:
934:
823:
756:
708:
631:
557:
24:
333:
329:
283:
248:
178:
146:
142:
126:
93:
239:
Lymphocytes can be further divided into three main types. These include
740:
375:
345:
228:
473:
Nanotechnology for
Hematology, Blood Transfusion, and Artificial Blood
973:
682:
600:"Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma"
240:
212:
208:
97:
88:. While extensive research has been done with regards to artificial
524:
Zinger, Assaf; Cooke, John P.; Taraballi, Francesca (2021-04-01).
364:
307:
215:
and control the degree to which other immune cells are activated.
130:
112:
659:"Biomimetic proteolipid vesicles for targeting inflamed tissues"
854:"Polymersomes as a potential platform for cancer immunotherapy"
18:
475:, Micro and Nano Technologies, Elsevier, pp. 451–461,
291:
that exhibit anti-inflammatory qualities. When loaded with
469:"Chapter 19 - Artificial white blood cells—WBC substitute"
382:
derived nanoghosts exhibit cancer targeting properties.
903:"Artificial polymeric cells for targeted drug delivery"
49:
39:
604:
European
Journal of Pharmaceutics and Biopharmaceutics
901:
Eniola, A. Omolola; Hammer, Daniel A. (2003-02-21).
530:Nanomedicine: Nanotechnology, Biology and Medicine
247:(NK) cells. B-cells become activated and produce
161:, whereas cells like lymphocytes are part of the
784:Frontiers in Bioengineering and Biotechnology
8:
324:Luekopolymersomes are polymer block-based
1050:
989:
869:
813:
795:
698:
273:
72:
414:
117:Some of the various kinds of leukocytes
1011:
1009:
462:
460:
458:
456:
454:
452:
450:
448:
446:
444:
442:
440:
438:
7:
847:
845:
843:
841:
839:
837:
835:
833:
651:
649:
593:
591:
589:
587:
585:
583:
581:
579:
577:
575:
519:
517:
515:
513:
436:
434:
432:
430:
428:
426:
424:
422:
420:
418:
386:Artificial Antigen Presenting Cells
16:Alternative method of immunotherapy
481:10.1016/b978-0-12-823971-1.00015-5
14:
23:
121:Leukocytes, otherwise known as
1:
919:10.1016/S0168-3659(02)00346-2
907:Journal of Controlled Release
82:Artificial white blood cells
871:10.1016/j.mtadv.2021.100203
320:Image of polymersomes (red)
190:, and extracellular traps.
1107:
616:10.1016/j.ejpb.2022.06.014
542:10.1016/j.nano.2021.102360
797:10.3389/fbioe.2022.883034
173:Through the mechanism of
858:Materials Today Advances
77:White Blood Cell (right)
38:, as no other articles
1035:10.1038/nnano.2012.212
370:
321:
284:lipid bilayer vesicles
279:
118:
78:
1023:Nature Nanotechnology
380:Mesenchymal stem cell
368:
342:poly(L-glutamic acid)
319:
277:
116:
76:
950:"Leuko-polymersomes"
729:Biomaterials Science
265:Current Advancements
163:active immune system
159:innate immune system
157:are involved in the
109:Leukocyte Physiology
966:2008FaDi..139..129H
954:Faraday Discussions
675:2016NatMa..15.1037M
402:polyethylene glycol
741:10.1039/C9BM01766F
371:
322:
280:
119:
79:
57:for suggestions.
47:to this page from
1091:Synthetic biology
1086:Blood substitutes
490:978-0-12-823971-1
352:Leukolike Vectors
317:
304:Leukopolymersomes
199:against viruses.
123:white blood cells
71:
70:
1098:
1065:
1064:
1054:
1013:
1004:
1003:
993:
974:10.1039/B717821B
945:
939:
938:
898:
892:
891:
873:
849:
828:
827:
817:
799:
775:
769:
768:
719:
713:
712:
702:
683:10.1038/nmat4644
669:(9): 1037–1046.
663:Nature Materials
653:
644:
643:
595:
570:
569:
521:
508:
507:
506:
505:
464:
318:
66:
63:
52:
50:related articles
27:
19:
1106:
1105:
1101:
1100:
1099:
1097:
1096:
1095:
1071:
1070:
1069:
1068:
1015:
1014:
1007:
947:
946:
942:
900:
899:
895:
851:
850:
831:
777:
776:
772:
721:
720:
716:
655:
654:
647:
597:
596:
573:
523:
522:
511:
503:
501:
491:
466:
465:
416:
411:
397:
388:
363:
354:
308:
306:
289:glucocorticoids
282:Leukosomes are
272:
267:
258:
243:, T-cells, and
237:
221:
205:
196:
171:
155:dendritic cells
111:
103:synthetic blood
90:red blood cells
67:
61:
58:
48:
45:introduce links
28:
17:
12:
11:
5:
1104:
1102:
1094:
1093:
1088:
1083:
1073:
1072:
1067:
1066:
1005:
940:
893:
829:
770:
735:(1): 333–341.
714:
645:
571:
509:
489:
413:
412:
410:
407:
396:
393:
387:
384:
362:
359:
353:
350:
305:
302:
271:
268:
266:
263:
257:
254:
245:natural killer
236:
233:
220:
217:
204:
201:
195:
192:
170:
167:
110:
107:
69:
68:
55:Find link tool
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
1103:
1092:
1089:
1087:
1084:
1082:
1079:
1078:
1076:
1062:
1058:
1053:
1048:
1044:
1040:
1036:
1032:
1028:
1024:
1020:
1012:
1010:
1006:
1001:
997:
992:
987:
983:
979:
975:
971:
967:
963:
959:
955:
951:
944:
941:
936:
932:
928:
924:
920:
916:
912:
908:
904:
897:
894:
889:
885:
881:
877:
872:
867:
863:
859:
855:
848:
846:
844:
842:
840:
838:
836:
834:
830:
825:
821:
816:
811:
807:
803:
798:
793:
789:
785:
781:
774:
771:
766:
762:
758:
754:
750:
746:
742:
738:
734:
730:
726:
718:
715:
710:
706:
701:
696:
692:
688:
684:
680:
676:
672:
668:
664:
660:
652:
650:
646:
641:
637:
633:
629:
625:
621:
617:
613:
609:
605:
601:
594:
592:
590:
588:
586:
584:
582:
580:
578:
576:
572:
567:
563:
559:
555:
551:
547:
543:
539:
535:
531:
527:
520:
518:
516:
514:
510:
500:
496:
492:
486:
482:
478:
474:
470:
463:
461:
459:
457:
455:
453:
451:
449:
447:
445:
443:
441:
439:
437:
435:
433:
431:
429:
427:
425:
423:
421:
419:
415:
408:
406:
403:
394:
392:
385:
383:
381:
377:
367:
360:
358:
351:
349:
347:
343:
340:, PCL, PTMC,
339:
338:poly(lactide)
335:
331:
327:
326:nanoparticles
303:
301:
298:
294:
293:dexamethasone
290:
285:
276:
269:
264:
262:
255:
253:
250:
246:
242:
234:
232:
230:
226:
218:
216:
214:
210:
202:
200:
193:
191:
189:
188:degranulation
185:
180:
176:
168:
166:
164:
160:
156:
152:
148:
144:
140:
136:
132:
128:
124:
115:
108:
106:
104:
99:
95:
91:
87:
83:
75:
65:
56:
51:
46:
42:
41:
37:
32:This article
30:
26:
21:
20:
1029:(1): 61–68.
1026:
1022:
957:
953:
943:
913:(1): 15–22.
910:
906:
896:
861:
857:
787:
783:
773:
732:
728:
717:
666:
662:
607:
603:
533:
529:
502:, retrieved
472:
398:
389:
372:
355:
323:
281:
259:
238:
222:
206:
197:
184:phagocytosis
172:
120:
81:
80:
59:
33:
1081:Blood cells
960:: 129–141.
610:: 157–174.
395:Limitations
297:doxorubicin
235:Lymphocytes
225:macrophages
194:Eosinophils
169:Neutrophils
151:lymphocytes
139:eosinophils
135:neutrophils
1075:Categories
864:: 100203.
790:: 883034.
536:: 102360.
504:2023-04-20
409:References
361:Nanoghosts
270:Leukosomes
249:antibodies
175:chemotaxis
86:leukocytes
53:; try the
40:link to it
1043:1748-3395
982:1364-5498
927:0168-3659
888:245631187
880:2590-0498
806:2296-4185
765:207938121
749:2047-4849
691:1476-4660
640:250282152
624:0939-6411
566:231677280
550:1549-9634
499:244208614
334:integrins
330:selectins
219:Monocytes
203:Basophils
179:cytokines
147:monocytes
143:basophils
94:platelets
62:June 2024
43:. Please
1061:23241654
1000:19048993
935:12618019
824:35757799
757:31714542
709:27213956
632:35787429
558:33476763
229:antigens
127:bacteria
1052:3751189
991:2714229
962:Bibcode
815:9214241
700:5127392
671:Bibcode
376:cytosol
346:dextran
256:History
241:B-cells
213:T-cells
209:enzymes
131:viruses
1059:
1049:
1041:
998:
988:
980:
933:
925:
886:
878:
822:
812:
804:
763:
755:
747:
707:
697:
689:
638:
630:
622:
564:
556:
548:
497:
487:
149:, and
98:cancer
36:orphan
34:is an
884:S2CID
761:S2CID
636:S2CID
562:S2CID
495:S2CID
1057:PMID
1039:ISSN
996:PMID
978:ISSN
931:PMID
923:ISSN
876:ISSN
820:PMID
802:ISSN
753:PMID
745:ISSN
705:PMID
687:ISSN
628:PMID
620:ISSN
554:PMID
546:ISSN
485:ISBN
344:and
332:and
92:and
1047:PMC
1031:doi
986:PMC
970:doi
958:139
915:doi
866:doi
810:PMC
792:doi
737:doi
695:PMC
679:doi
612:doi
608:177
538:doi
477:doi
129:or
1077::
1055:.
1045:.
1037:.
1025:.
1021:.
1008:^
994:.
984:.
976:.
968:.
956:.
952:.
929:.
921:.
911:87
905:.
882:.
874:.
862:13
860:.
856:.
832:^
818:.
808:.
800:.
788:10
786:.
782:.
759:.
751:.
743:.
731:.
727:.
703:.
693:.
685:.
677:.
667:15
665:.
661:.
648:^
634:.
626:.
618:.
606:.
602:.
574:^
560:.
552:.
544:.
534:33
532:.
528:.
512:^
493:,
483:,
471:,
417:^
186:,
165:.
145:,
141:,
137:,
1063:.
1033::
1027:8
1002:.
972::
964::
937:.
917::
890:.
868::
826:.
794::
767:.
739::
733:8
711:.
681::
673::
642:.
614::
568:.
540::
479::
64:)
60:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
